Acute Hyperglycemia Associated with Anti-Cancer Medication. - Wikidata - awgldk - TriplyDB

Acute Hyperglycemia Associated with Anti-Cancer Medication.

Acute Hyperglycemia Associated with Anti-Cancer Medication.

http://www.wikidata.org/entity/Q37723241

about

Acute Hyperglycemia Associated with Anti-Cancer Medication.

http://www.wikidata.org/entity/Q37723241

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@en

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@nl

type

label

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@en

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@nl

prefLabel

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@en

Acute Hyperglycemia Associated with Anti-Cancer Medication.

@nl

P1433

Q37723241-5DD50E33-F572-407A-A886-30B10C0E5D7E

P1476

Q37723241-AA0E8B6C-265C-402F-B692-18BB75F79475

P2093

Q37723241-3AFB5ACC-A4F0-423F-82CC-E62CD2ADA6AF

P2860

Q37723241-0089CD6B-9952-4894-B7F8-ECD9C21C4842

Q37723241-07B4FD35-82E9-4ECB-83F2-9CA90DF6709A

Q37723241-123C8EBB-2D0E-45FE-8BA5-9244192B569D

Q37723241-171B82E2-9FDC-424F-907B-61CED079525D

Q37723241-23B0563A-DB27-4233-84E6-F3DB2406E6C7

Q37723241-2516B44D-9D0F-46A2-AA37-AB4DD75204C2

Q37723241-2CE61F5B-6596-4CE9-9073-EB25FC1E4844

Q37723241-2DECED69-32B9-4D40-A1A1-14CFC10AFC82

Q37723241-3831EFFC-FC58-4396-84CC-5C6CFEF6C193

Q37723241-3D23FB43-8B30-4C57-BD92-99FD5E7B7C58

P304

Q37723241-EA8B5718-552E-4CBF-AD2F-8C06FF6E376F

P31

Q37723241-00E4B2A5-6E0F-44D6-95CE-F3288D65215B

P356

Q37723241-96398886-0C03-48CF-A1E6-E1C1802DC27E

P433

Q37723241-9F0ECFC8-C350-497A-A722-3E32B743F262

P478

Q37723241-C3EBC0F1-417F-43D3-AFEA-476DE8888B80

P50

Q37723241-EC0665DD-6B11-4DB3-BD74-CE486E2D83E9

P577

Q37723241-54EE457C-76F1-4F7C-B78C-71B0B35B0B35

P698

Q37723241-8804E32C-BAC7-429C-AA83-FE8F31FF14ED

P921

Q37723241-F09D1B91-BB69-4CB4-A877-36C9AB8FC7D9

P932

Q37723241-798120C4-6F20-4357-A640-6C9216719890

P356

ENM.2017.32.1.23

P1433

Endocrinology and metabolism : EnM

P1476

Acute Hyperglycemia Associated with Anti-Cancer Medication

@en

P2093

Yul Hwangbo

http://www.w3.org/2001/XMLSchema#string

P2860

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Preven

Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

P304

23-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3803/ENM.2017.32.1.23

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28345313

http://www.w3.org/2001/XMLSchema#string

P921

P932

5368117

http://www.w3.org/2001/XMLSchema#string